Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 1.
doi: 10.1111/bju.16870. Online ahead of print.

Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies

Jordan Santucci  1   2 , Peter Stapleton  3 , Marlon Perera  4   5   6 , Joseph Ischia  4 , Declan Murphy  5   7 , Damien Bolton  4   6 , Nathan Lawrentschuk  5   6   8 , Mark Frydenberg  1   9 , Niranjan Sathianathen  4
Affiliations
Review

Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies

Jordan Santucci et al. BJU Int. .

Abstract

Objectives: To evaluate the oncological safety of testosterone replacement therapy (TRT) in hypogonadal patients with prostate cancer, as testosterone deficiency (TD) rises in prevalence with age and in prostate cancer may be treatment-related, whilst contributing to poor health outcomes.

Patients and methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Medline, EMBASE, PubMed, and Scopus were searched. Studies were included assessing progression and biochemical recurrence in men with prostate cancer and TD receiving TRT.

Results: Searches yielded 4067 studies, of which 19 were included: five in active surveillance, 10 post-radical prostatectomy (RP), six post-radiotherapy. Pooled meta-analysis was not valid due to insufficient number of comparative studies and significant clinical and methodological heterogeneity. Progression rates on active surveillance ranged from 0% to 32% and did not differ significantly to non-exposed controls on retrospective comparison at follow-up as long as 70 months. Biochemical recurrence rates in TRT-exposed cohorts were low post-definitive treatment ranging from 0% to 7% post-RP to 0-6% post-radiotherapy (± androgen deprivation therapy) with up to 60 months of follow-up. Overall certainty of TRT oncological safety is limited by lack of long-term, prospective, controlled comparative data and lack of assessment of survival outcomes.

Conclusions: Retrospective evidence supports cautious use of TRT in low-intermediate-risk disease on active surveillance and favourable localised disease post-RP or post-radiotherapy with appropriate prostate-specific antigen responses. Diligent patient selection and monitoring are required until randomised controlled trial data are available to inform safe management of TD in prostate cancer.

Keywords: hypogonadism; low testosterone; prostate cancer; testosterone deficiency; testosterone replacement therapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Jia H, Sullivan CT, McCoy SC, Yarrow JF, Morrow M, Borst SE. Review of health risks of low testosterone and testosterone administration. World J Clin Cases 2015; 3: 338–344
    1. Mulhall JP, Trost LW, Brannigan RE et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol 2018; 200: 423–432
    1. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality‐of‐life analysis from CaPSURE. Cancer of the prostate strategic urologic research endeavor. Urology 1999; 54: 503–508
    1. Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early‐stage prostate cancer. Cancer 2007; 109: 2239–2247
    1. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med 2008; 358: 1250–1261

LinkOut - more resources